case_images: PMC11250276_01
case_images: a Optical coherence tomography (OCT) of the right eye before treatment demonstrated non-center involving intraretinal fluid, VMA, and drusen. Best corrected visual acuity (BCVA) was 20/60 in the right eye and count fingers at 1 foot in the left eye. b OCT after the third aflibercept injection in the right eye showed progression of VMA. c OCT after the fourth aflibercept injection showed progression of VMA to VMT with tenting of the fovea. d OCT two and a half months after the sixth aflibercept injection revealed a FTMH. BCVA in the right eye was 20/200.
case_images: cop-2024-0015-0001-537777_F01.jpg
case_images: PMC11250276_01_cop-2024-0015-0001-537777_F01.jpg
case_images: F1
case_images: OD and multiple macular drusen OU. OCT demonstrated intraretinal fluid, vitreomacular adhesion (VMA), and drusen OD (shown in Fig. 1a), and intraretinal fluid over a disciform scar OS. After the third and fourth aflibercept injection OD, progression of VMA was noted on OCT (shown in Fig. 1b, c). FTMH (shown in Fig. 1d). Following informed consent, the patient underwent prompt treatment with 25-gauge pars plana vitrectomy, internal limiting membrane peeling, and 20% SF6 gas injection
case_images: a Optical coherence tomography (OCT) obtained on postoperative day 8 demonstrated successful closure of a FTMH. BCVA on postoperative day 8 was 20/80-2 in the right eye and count finger at 3 feet in the left eye. One month following successful vitrectomy, the patient resumed aflibercept injections at 6 weeks intervals. OCT at postoperative month 2 (b), month 5 (c), month 8 (d), and 1 year 3 months (e) revealed progression of post-ILM peel and AMD-associated atrophy temporally, and no macular hole recurrence. Visual acuity returned to the patient's baseline of 20/60.
case_images: cop-2024-0015-0001-537777_F02.jpg
case_images: PMC11250276_01_cop-2024-0015-0001-537777_F02.jpg
case_images: F2
case_images: OD with face down positioning for 1 week. On postoperative day 8, his vision improved to 20/80-2 and an OCT confirmed macular hole closure (shown in Fig. 2a). Reevaluations over a 15-month follow-up period revealed no recurrence of FTMH (shown in Fig. 2b-e).